Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082826 | PMC |
J Sex Med
January 2025
The Center for Men's Health Stritch School of Medicine, Maywood, IL 60153, United States.
Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.
Aim: We now assess the impact of Optilume BPH procedure on sexual function.
Methods: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms.
J Steroid Biochem Mol Biol
January 2025
Department of Pathology, University of Illinois Chicago, Chicago, IL, USA; University of Illinois Cancer Center, Chicago, IL, USA. Electronic address:
Epidemiological data from as early as the 1930s documented a dramatic racial disparity in prostate cancer incidence, survival, and mortality rates among Black men-a trend that persists to this day. Black men are disproportionately burdened by prostate cancer, developing the disease at younger ages, facing more aggressive and lethal forms, and ultimately experiencing double the mortality rate of men of European descent. Investigating the multifactorial contributors to this racial disparity has been extensive, but results have often been inconsistent or inconclusive, making it difficult to pinpoint clear correlations.
View Article and Find Full Text PDFCureus
January 2025
Clive O. Callender Outcomes Research Center, Howard University College of Medicine, Washington, D.C., USA.
Introduction: Prostate cancer stands as one of the most diagnosed malignancies among men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA), millions more Americans now have health insurance coverage, potentially influencing healthcare access and subsequent outcomes for various illnesses, including prostate cancer. Yet, the direct correlation between Medicaid expansion and cancer-specific survival among individuals with prostate cancer remains an area warranting comprehensive exploration.
View Article and Find Full Text PDFPract Radiat Oncol
December 2024
Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Quebec, Canada.
Purpose: Local recurrence of prostate cancer (PCa) after radiation therapy (RT) typically occurs at the site of dominant tumor burden, and recent evidence confirms that magnetic resonance imaging (MRI) guided tumor dose escalation improves outcomes. With the emergence of prostate-specific membrane antigen (PSMA) positron emission tomography (PET), we hypothesize that PSMA-PET and MRI may not equally depict the region most at risk of recurrence after RT.
Methods And Materials: Patients with intermediate- to high-risk PCa and MRI plus PSMA-PET performed before RT were identified.
Transl Androl Urol
December 2024
Department of Urology and Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Background: The global prevalence of lower urinary tract symptoms suggestive of benign prostate hyperplasia (LUTS/BPH) escalates, with obesity recognized as a major contributing factor. However, the association between the relative fat mass (RFM) and LUTS/BPH remains unexplored. This 7-year follow-up study aimed to investigate the cross-sectional and longitudinal relationships between RFM and LUTS/BPH.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!